Significance of EASI-75 Response Rates in Patients with Skin of Color on Lebrikizumab

In light of the ADmirable study’s new phase 3b findings on lebrikizumab (Ebglyss) treatment of atopic dermatitis in adult and adolescent patients with skin of color, HCPLive interviewed Andrew Alexis, MD, MPH, ADmirable study investigator, professor of clinical dermatology, and vice-chair for diversity and inclusion at Weill Cornell Medicine.

The trial’s primary efficacy measure had been 75% or greater improvement in the Eczema Area and Severity Index (EASI). Participants in the ADmirable analysis had Fitzpatrick skin phototypes IV, V, or VI and self-identified as a race other than White. EASI-75 response rates were shown to have increased through Week 24, particularly in patients with skin phototype VI. Alexis was asked how this informs expectations around response kinetics or treatment duration in patients with skin of color.

Alexis noted that response rates had been strong at Week 16. He added that in a cohort of patients who were considered non-responders at Week 16, when these patients remained on treatment with lebrikizumab every 2 weeks, almost half of them went on to become responders by the 24-week mark.

Alexis has reported advisory/consulting fees from companies including Lilly.

References

1. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Accessed June 18, 2025. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and.